NxStage Medical, Inc. (NXTM) Receives $30.00 Consensus PT from Analysts
NxStage Medical, Inc. (NASDAQ:NXTM) has been given a consensus rating of “Hold” by the ten ratings firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating and eight have issued a hold rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $30.00.
A number of brokerages have issued reports on NXTM. Leerink Swann lowered NxStage Medical from an “outperform” rating to a “market perform” rating and increased their price target for the stock from $28.00 to $30.00 in a research note on Tuesday, August 22nd. Zacks Investment Research lowered NxStage Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Canaccord Genuity reiterated a “hold” rating and issued a $30.00 price target on shares of NxStage Medical in a research note on Tuesday, October 17th. Finally, Northland Securities reiterated a “hold” rating and issued a $30.00 price target on shares of NxStage Medical in a research note on Wednesday, November 8th.
In other news, President Joseph E. Turk, Jr. sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $27.56, for a total transaction of $27,560.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Winifred L. Swan sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $25.73, for a total value of $90,055.00. The disclosure for this sale can be found here. Insiders sold a total of 12,300 shares of company stock valued at $331,126 in the last quarter. 4.70% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the company. Prudential Financial Inc. purchased a new position in shares of NxStage Medical during the third quarter valued at about $202,000. Amalgamated Bank grew its position in shares of NxStage Medical by 7.1% during the second quarter. Amalgamated Bank now owns 8,357 shares of the medical device company’s stock valued at $210,000 after purchasing an additional 553 shares in the last quarter. Athos Capital Ltd purchased a new position in shares of NxStage Medical during the third quarter valued at about $557,000. Suntrust Banks Inc. lifted its holdings in shares of NxStage Medical by 2.3% in the 2nd quarter. Suntrust Banks Inc. now owns 9,480 shares of the medical device company’s stock valued at $237,000 after acquiring an additional 209 shares during the last quarter. Finally, BNP Paribas Arbitrage SA lifted its holdings in shares of NxStage Medical by 217.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 9,676 shares of the medical device company’s stock valued at $243,000 after acquiring an additional 6,624 shares during the last quarter. Hedge funds and other institutional investors own 85.68% of the company’s stock.
Shares of NxStage Medical (NASDAQ NXTM) traded up $0.17 during trading on Friday, reaching $26.06. The company had a trading volume of 590,144 shares, compared to its average volume of 799,763. NxStage Medical has a one year low of $20.45 and a one year high of $30.80.
WARNING: This news story was first reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/nxstage-medical-inc-nxtm-receives-30-00-consensus-pt-from-analysts/1762197.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with Analyst Ratings Network's FREE daily email newsletter.